Statins and myotoxicity: a therapeutic limitation

Area of Science:

• Pharmacology and Toxicology
• Cardiovascular Medicine
• Biochemistry

Background:

• Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are primary treatments for hypercholesterolemia and dyslipidemia, conditions linked to coronary heart disease and atherosclerosis.
• Despite their efficacy, statins are associated with adverse events, notably myotoxicity, ranging from myalgia to severe rhabdomyolysis, a rare but serious muscle-wasting disorder.
• Statin-induced rhabdomyolysis can lead to irreversible renal damage via complex biochemical pathways, highlighting the importance of understanding its mechanisms.

Purpose of the Study:

• To review the concerns surrounding statin-associated myotoxicity, including its mechanisms, risk factors, and management.
• To explore the role of hepatic-specific distribution in minimizing statin-induced muscle damage.
• To discuss the influence of drug interactions and pharmacogenomic factors on statin tolerability and efficacy.

Main Methods:

• Review of existing literature on HMG-CoA reductase inhibitors, focusing on their efficacy, adverse effects, and mechanisms of toxicity.
• Analysis of factors influencing statin distribution, including physicochemical and pharmacokinetic properties, and transporter-mediated uptake.
• Examination of the interplay between concomitant medications, genetic variations (e.g., CYP polymorphism), and statin-induced myopathy.

Main Results:

• Hepatic-specific distribution of statins is a key factor in mitigating myotoxicity.
• Drug interactions and pharmacogenomic factors, such as CYP polymorphism, significantly contribute to inter-individual variations in statin efficacy and tolerability.
• Pathophysiological mechanisms involve alterations in cholesterol:phospholipid ratios, isoprenoid levels, GTP binding proteins, and apoptosis, though a reliable preclinical approach is lacking.

Conclusions:

• While statin-associated myotoxicity can impact patient compliance and quality of life, its low incidence and generally mild presentation do not negate the clinical benefits of statins.
• Medical management strategies are pivotal for ensuring patient compliance with statin therapy.
• Judicious use of statins is essential to minimize the risk of developing clinically significant myopathy.